Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PIV5-based H7N9 vaccine
- Development stage
- Preclinical
- Lead developer
- CyanVac
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
The PIV5-based H7N9 vaccine is a live, intranasal viral vector vaccine candidate designed to protect against infection by the avian influenza A (H7N9) virus. It uses Parainfluenza Virus 5 (PIV5) as a vector to express the hemagglutinin (HA) protein from the H7N9 influenza strain. The mechanism of action involves inducing both humoral and cellular immune responses against the HA antigen, providing protection even in the absence of detectable antibody responses. Preclinical studies have demonstrated that a single intranasal dose can confer complete protection in animal models challenged with lethal doses of H7N9[2]. The platform allows for rapid development and needle-free delivery via mucosal immunization. Blue Lake Biotechnology and its affiliate CyanVac are developing this technology as part of their broader pipeline targeting pandemic threats[1][4].
- Other names
- recombinant parainfluenza virus 5 expressing HA of H7N9rPIV5-H7rPIV-5-H7rPIV 5-H7
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on PIV5-based H7N9 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PIV5-based H7N9 vaccine.